Xencor, Inc.
NASDAQ•XNCR
CEO: Dr. Bassil I. Dahiyat Ph.D.
セクター: Healthcare
業種: Biotechnology
上場日: 2013-12-03
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.
連絡先情報
時価総額
$849.99M
PER (TTM)
-9.4
17.6
配当利回り
--
52週高値
$18.69
52週安値
$6.92
52週レンジ
順位46Top 59.5%
3.5
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 3.5 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$28.24M+0.00%
直近4四半期の推移
EPS
-$0.09+0.00%
直近4四半期の推移
フリーCF
-$52.85M+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Total Revenue Increased 13.7% Total revenues reached 125.58M USD, up 13.7% from 110.49M USD in 2024, driven by licensing events.
Net Loss Significantly Reduced Net loss attributable to Xencor narrowed to 91.92M USD, a 60.5% reduction compared to 232.62M USD loss in 2024.
Milestone Revenue Recognized Recognized 45.30M USD in milestone revenue during 2025, including payments from Incyte and Vir Bio clinical study initiations.
Cash Position Strengthened Cash, cash equivalents, and restricted cash totaled 54.36M USD at year-end, increasing by 31.7% from prior year.
リスク要因
Success Depends on XmAb Platform Success relies on expanding XmAb technology to build marketable products; regulatory approval is not certain for candidates.
Future Financing Required Anticipates incurring significant losses; additional financing is required, risking substantial dilution for current stockholders.
Clinical Trial Uncertainty Remains Clinical trials are expensive, uncertain, and results may not predict future success, potentially delaying regulatory approval.
Ongoing Intellectual Property Litigation Facing patent infringement suit from Merus; adverse ruling could halt commercialization or result in monetary damages.
見通し
Advance Key Oncology Programs Focus remains on advancing wholly owned T-cell engaging candidates XmAb819, XmAb541, and XmAb808 in oncology.
Expand Autoimmune Pipeline Progress Initiating first-in-human studies for XmAb412 in 2026; XmAb942 Phase 2b study underway for IBD treatment.
Leverage Partnership Revenue Streams Expect continued revenue generation from licensing and collaboration agreements, retaining rights for prioritized internal programs.
Protect Proprietary Technology Portfolio Seeking to protect proprietary XmAb technologies and drug candidates by filing and prosecuting patents in key jurisdictions.
同業比較
売上高 (TTM)
$234.60M
$175.11M
$125.58M
粗利益率 (最新四半期)
199.8%
100.0%
97.3%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| TNGX | $2.17B | -21.4 | -50.3% | 8.4% |
| ANAB | $1.86B | -135.9 | 1813.8% | 79.8% |
| RLAY | $1.77B | -6.2 | -43.2% | 5.2% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-4.8%
横ばい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要
深度リサーチ
次回決算:2026年5月5日
EPS:-
|売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし